Testing outcomes with EGFR pills for uncommon lung cancer mutations
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how well an EGFR-targeted pill (called an EGFR-TKI) works for people with advanced lung cancer that has an uncommon EGFR mutation. It may help doctors understand which patients benefit most and improve survival outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have advanced non-small cell lung cancer confirmed by a tissue biopsy.
- Your cancer type is not squamous (it’s a non-squamous type).
- Your tumor has an uncommon EGFR mutation.
- You can safely take chemotherapy treatments (no known reasons you cannot).
- You are not currently pregnant and not breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests three different targeted pills (osimertinib, afatinib, dacomitinib) in people with advanced EGFR-mutated lung cancer who haven't had targeted therapy before. The goal is to find which pill works best and has the fewest side effects.
This study looks at how well a third-generation EGFR-targeted pill works after surgery for patients with stage IA non-small cell lung cancer that has certain high-risk features and an EGFR mutation. The goal is to see if this treatment helps prevent the cancer from coming back.
This trial tests an experimental pill called Sutetinib for people with advanced non-small cell lung cancer that has a rare EGFR gene change. It aims to see if the drug can shrink tumors and improve survival.
This trial tests if adding gumarontinib to a third-generation EGFR-targeted drug can help people with advanced non-small cell lung cancer whose cancer grew while on an EGFR-TKI and has a certain change (MET amplification). The goal is to see if this combination can overcome resistance.
This trial tests an experimental pill called BEBT-109 for people with a specific type of lung cancer (EGFR exon 20 insertion mutation) that has gotten worse after chemotherapy. The study aims to see if this targeted therapy can shrink tumors or slow cancer growth.
This trial tests combining an EGFR-targeted pill (like osimertinib) with the intravenous drug bevacizumab for people with advanced non-small cell lung cancer that has an EGFR mutation and has not been treated before. The goal is to see if this combination works better when guided by a special blood test that finds cancer cells.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.